# A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

> **NCT00169156** · PHASE2 · COMPLETED · sponsor: **Lymphoma Study Association** · enrollment: 27 (actual)

## Conditions studied

- Untreated T-cell Angioimmunoblastic Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Prednisone
- **DRUG:** Doxorubicine
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00169156
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-12
- **Final completion:** 2012-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169156, "A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00169156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*